Role of eosinophilic chronic rhinosinusitis in  switching to benralizumab treatment in mepolizumab responders
.

CONCLUSION: Our findings imply that in responders to mepolizumab, there may be a higher response rate to benralizumab in patients with ECRS than in those without. PMID: 32831163 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research